SUTRO BIOPHARMA INC

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

STRO$10.61+10.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share data)

	December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$69,268	$47,254
Marketable securities	264,413	255,090
Investment in equity securities	41,937	32,020
Accounts receivable	36,078	7,122
Prepaid expenses and other current assets	9,846	11,667
Total current assets	421,542	353,153
Property and equipment, net	21,940	24,621
Operating lease right-of-use assets	22,815	26,443
Other non-current assets	3,567	1,855
Restricted cash	872	872
Total assets	$470,736	$406,944
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$9,440	$4,797
Accrued compensation	14,686	13,142
Deferred revenue-current	20,666	16,759
Operating lease liability-current	6,420	4,585
Debt-current	4,061	12,500
Accrued expenses and other current liabilities	38,473	14,764
Total current liabilities	93,746	66,547
Deferred revenue, non-current	53,379	89,885
Operating lease liability-non-current	23,154	29,574
Debt-non-current	-	3,771
Deferred royalty obligation related to the sale of future royalties	149,114	-
Other non-current liabilities	1,694	119
Total liabilities	321,087	189,896
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value — 10,000,000 shares authorized as of December 31, 2023 and 2022; 0 shares issued and outstanding as of December 31, 2023 and 2022	-	-
Common stock, $0.001 par value — 300,000,000 shares authorized as of December 31, 2023 and 2022; 61,009,829 and 57,499,541 shares issued and outstanding as of December 31, 2023 and 2022, respectively	61	58
Additional paid-in-capital	708,975	670,223
Accumulated other comprehensive income (loss)	21	(618)
Accumulated deficit	(559,408)	(452,615)
Total stockholders’ equity	149,649	217,048
Total Liabilities and Stockholders’ Equity	$470,736	$406,944

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.